BioVie: Potential Blockbuster Late-Stage Programs Targeting Alzheimer’s & Parkinson’s

BioVie (Nasdaq: BIVI) is poised for significant catalysts in 2023, including data read out from its Alzheimer’s Phase 3 trial, expected in Q3 2023, as well as interim data read outs
from the Company’s planned Phase 3 study in Parkinson’s. BioVie has multiple other
efforts underway that may create additional catalysts and will be announced publicly
when the Company deems appropriate. Learn more at: https://www.redchip.com/stocks/bivi